• Top in hem/onc: COVID-19 and VTE risk, CAR T-cell therapy approval

    9 days ago - By Healio

    Researchers in China identified an increased risk for symptomatic venous thromboembolism in patients hospitalized with COVID-19. It was the top story in hematology/oncology last week.
    The FDA approval of the first chimeric antigen receptor T-cell therapy for multiple myeloma was another top story. According to the agency, Abecma (idecabtagene vicleucel; Bristol Myers Squibb, bluebird bio) attacks the B-cell maturation antigen when it is expressed on the surface of cancer cells.
    Read these and more top stories in hematology/oncology below:
    Patients with COVID-19 at high risk for symptomatic
    Read more ...